Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Business
Archived
•
October 2, 2026
•
2 views
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Source: CNBC Top | https://search.cnbc.com/rs/search/combinedcms/view.xml?partnerId=wrss01&id=100003114 - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



